Stem cell transplantation for mantle cell lymphoma: if, when and how?
Although the prognosis for mantle cell lymphoma (MCL) patients has improved in recent years, the outlook for those with advanced or recurrent disease remains poor. High-dose chemotherapy and autografting performed early in responding patients appears to be a method to extend progression-free survival (PFS) and overall survival (OS). The use of monoclonal antibody therapy added into the initial therapy and in the peritransplant period may improve on these results. Myeloablative allogeneic transplant appears to be a modality capable of providing curative therapy, but is plagued by a high treatment-related mortality, especially in older patients. Reduced-intensity conditioning allografting have fewer problems associated with the initial phase of transplant and hence may be preferred for those patients for whom an allograft is considered but have comorbid conditions or age issues that preclude a full allograft. Long-term results are lacking and the side effects associated with chronic GVHD may be as significant and debilitating. Trials designed to look at newly diagnosed patients with MCL examining the outcomes after planned autologous and allogeneic transplant as part of the initial management are needed to confirm the role of these various modalities in the overall therapy of this poor-outcome lymphoma.
Kiss
T L
TL
Hematology-Oncology, Hopital Maisonneuve Rosemont, University of Montreal, Montreal, Quebec, Canada.
Mollee
P
P
Lazarus
H M
HM
Lipton
J H
JH
D002986:Clinical Trials as Topic; D006801:Humans; D020522:Lymphoma, Mantle-Cell / Q000628:therapy*; D015337:Multicenter Studies as Topic; D033581:Stem Cell Transplantation / Q000379:methods*